Vertex Pharmaceuticals Incorporated (VRTX)
Company Info
Highlights
$111.55B
-$3.83
2.59
$11.09B
$9.54B
-$228.00M
$377.85 - $519.88
$500.30
1.66%
2.24
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Vertex Pharmaceuticals Incorporated (VRTX) returned 8.93% year-to-date (YTD) and -0.45% over the past 12 months. Over the past 10 years, VRTX delivered an annualized return of 13.11%, outperforming the S&P 500 benchmark at 10.87%.
VRTX
8.93%
-9.72%
-5.81%
-0.45%
8.75%
13.11%
^GSPC (Benchmark)
1.30%
12.94%
1.49%
12.48%
15.82%
10.87%
Monthly Returns
The table below presents the monthly returns of VRTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 14.65% | 3.92% | 1.05% | 5.09% | -13.91% | 8.93% | |||||||
| 2024 | 6.51% | -2.92% | -0.65% | -6.03% | 15.92% | 2.94% | 5.76% | 0.03% | -6.21% | 2.34% | -1.65% | -13.98% | -1.03% |
| 2023 | 11.88% | -10.15% | 8.54% | 8.14% | -5.04% | 8.76% | 0.12% | -1.14% | -0.17% | 4.13% | -2.02% | 14.68% | 40.90% |
| 2022 | 10.68% | -5.36% | 13.46% | 4.69% | -1.67% | 4.89% | -0.49% | 0.48% | 2.76% | 7.76% | 1.41% | -8.73% | 31.50% |
| 2021 | -3.07% | -7.22% | 1.10% | 1.54% | -4.39% | -3.36% | -0.02% | -0.64% | -9.44% | 1.95% | 1.09% | 17.47% | -7.08% |
| 2020 | 3.70% | -1.33% | 6.21% | 5.57% | 14.63% | 0.82% | -6.31% | 2.62% | -2.51% | -23.43% | 9.31% | 3.77% | 7.94% |
| 2019 | 15.21% | -1.13% | -2.54% | -8.14% | -1.66% | 10.35% | -9.14% | 8.04% | -5.89% | 15.38% | 13.44% | -1.26% | 32.13% |
| 2018 | 11.35% | -0.50% | -1.84% | -6.03% | 0.55% | 10.36% | 2.99% | 5.34% | 4.52% | -12.08% | 6.69% | -8.34% | 10.58% |
| 2017 | 16.56% | 5.53% | 20.67% | 8.18% | 4.48% | 4.26% | 17.81% | 5.74% | -5.29% | -3.82% | -1.33% | 3.86% | 103.42% |
| 2016 | -27.88% | -5.80% | -7.02% | 6.10% | 10.45% | -7.65% | 12.76% | -2.57% | -7.72% | -13.01% | 7.58% | -9.73% | -41.45% |
| 2015 | -7.29% | 8.43% | -1.22% | 4.50% | 4.06% | -3.75% | 9.33% | -5.54% | -18.33% | 19.78% | 3.70% | -2.73% | 5.92% |
| 2014 | 6.38% | 2.30% | -12.54% | -4.27% | 6.74% | 31.03% | -6.09% | 5.24% | 20.03% | 0.29% | 4.65% | 0.78% | 59.89% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of VRTX is 50, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vertex Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vertex Pharmaceuticals Incorporated was 91.77%, occurring on Nov 11, 2003. Recovery took 2676 trading sessions.
The current Vertex Pharmaceuticals Incorporated drawdown is 15.11%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.77% | Nov 3, 2000 | 757 | Nov 11, 2003 | 2676 | Jul 2, 2014 | 3433 |
| -70.17% | Feb 25, 1997 | 383 | Aug 31, 1998 | 363 | Feb 8, 2000 | 746 |
| -60.87% | Jan 7, 1992 | 114 | Jun 18, 1992 | 335 | Oct 14, 1993 | 449 |
| -55.26% | Mar 7, 2000 | 29 | Apr 14, 2000 | 43 | Jun 16, 2000 | 72 |
| -49.1% | Aug 20, 2015 | 340 | Dec 22, 2016 | 142 | Jul 19, 2017 | 482 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Vertex Pharmaceuticals Incorporated, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -5.4%.
Valuation
The Valuation section provides an overview of how Vertex Pharmaceuticals Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for VRTX compared to other companies in the Biotechnology industry. VRTX currently has a PEG ratio of 2.6. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VRTX relative to other companies in the Biotechnology industry. Currently, VRTX has a P/S ratio of 10.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VRTX in comparison with other companies in the Biotechnology industry. Currently, VRTX has a P/B value of 6.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |